Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioTheranostics, Inc.
Private Company Edition: New capital for health care and life science innovations include a fund for royalty deals, additional anti-infective funding, early-stage money and public health-focused cash. Also, Day One reveals a $130m series B venture round and Notch closes an $85m series A round.
Hologic’s recent buy-outs put it in a strengthened growth and competitive position beyond COVID.
The new-generation of tests from Myriad and NanoString have outperformed Genomic Health's Oncotype Dx in predicting which breast cancer patients are at low-risk for a recurrence in five to ten years, and therefore do not need to be on extended endocrine therapy.
Roche's diabetes business continues to struggle as third quarter results show sales in the division dipped by 3%, while Quest Diagnostics' bottom line took a hit from special charges. Meanwhile, bioMérieux said third-quarter revenues increased by 7%; Danaher is finalizing its acquisition of Cepheid.
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Diagnostic Imaging Equipment & Supplies
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing